Kazia Therapeutics (KZIA) Accounts Payables (2017 - 2025)

Kazia Therapeutics' Accounts Payables history spans 6 years, with the latest figure at $6.5 million for Q2 2025.

  • For Q2 2025, Accounts Payables fell 34.75% year-over-year to $6.5 million; the TTM value through Jun 2025 reached $6.5 million, down 34.75%, while the annual FY2025 figure was $6.5 million, 34.75% down from the prior year.
  • Accounts Payables reached $6.5 million in Q2 2025 per KZIA's latest filing, down from $9.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $9.9 million in Q2 2024 to a low of $2.7 million in Q2 2022.
  • Average Accounts Payables over 4 years is $5.5 million, with a median of $4.7 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: soared 243.19% in 2024, then crashed 34.75% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $2.7 million in 2022, then increased by 7.46% to $2.9 million in 2023, then skyrocketed by 243.19% to $9.9 million in 2024, then tumbled by 34.75% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Accounts Payables are $6.5 million (Q2 2025), $9.9 million (Q2 2024), and $2.9 million (Q2 2023).